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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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SATURDAY, DECEMBER 16, 2017

Ionis scientists provide initial assessment of
successful Phase 1/2a Huntington’s disease trial and
discuss next steps
After announcing December 11 that Ionis Pharmaceuticals’ gene-silencing
drug for Huntington’s disease safely reduced the production of the toxic
HD protein, company officials analyzed the firm’s successful Phase 1/2a
clinical trial and discussed the next step: larger trials that are designed to
test IONIS-HTTRx’s efficacy in alleviating symptoms by modifying the
course of the disease.
I met with two lead scientists from Ionis’ HD team at company
headquarters in Carlsbad, CA: Frank Bennett, Ph.D., Ionis senior vice
president of research and the franchise leader for the company’s neurology
programs, and Anne Smith, Ph.D., the Ionis director of clinical
development and the individual responsible for the day-to-day
management of the trial.
Drs. Bennett and Smith stressed that, because the two-year trial ended just
last month, they could provide only an initial assessment of the results.
The company plans to present detailed clinical trial findings at medical
conferences in early 2018 and then publish the results in scientific
journals.
Ionis will transfer administration of the next clinical trial phases to Roche,
a key partner in the project since 2013. Roche now holds the license to
IONIS-HTTRx, will lead further development, and handle all potential
sales. Phase 1/2a took place in Canada, England, and Germany, but the
next phase will have sites in the U.S. and other countries, to be determined
next year by Roche. Ionis will continue to play an advisory role in the
project.
“We are very appreciative of the community, and the patience that the
community has exhibited,” Dr. Bennett said. “We understand how
important this is for the HD community. We’re very pleased it’s going
forward. The community has been very respectful towards the company
and has allowed us to conduct this study in a way that was very robust.”
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Drs. Bennett and Smith focused on how the trial revealed a reduction in
the mutant huntingtin protein that “substantially exceeded our
expectations,” according to the December 11 press release. The key, initial
piece of trial data came from the measurement of the protein in the HD
patients’ cerebrospinal fluid (CSF). Other trial data such as brain scans
and blood samples will become available later.
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IONIS-HTTRx and other Ionis drugs are antisense oligonucleotides (ASOs,
artificial strands of DNA), which alter the expression of genes. In August
2016, Ionis and its partner Biogen actually halted a Phase 3 trial of an
Ionis ASO in infants with spinal muscular atrophy (a motor neuron
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disease) because the drug was extending their lives. The FDA (Food and
Drug Administration) approved the drug, with the commercial name
SPINRAZA, in December 2016.
In October, Ionis and Biogen won a biotechnology prize for SPINRAZA
(click here to read more). Ionis is also collaborating with Biogen to develop
a drug for amyotrophic lateral sclerosis (Lou Gehrig’s disease).
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Dr. Frank Bennett (left) with Gene Veritas (aka Kenneth P. Serbin) and
Dr. Anne Smith (photo by Kristina Bowyer, Ionis)
Following are key excerpts from the interview.
Compelling changes in mutant huntingtin levels
GV: How did patients react to the intrathecal administration of the drug,
that is, via a spinal tap?
AS: We didn’t hear from any of the physicians that there were any
difficulties. There was probably some nervousness, but there were few side
effects, and that ones they had were manageable. I think it’s telling that all
46 patients completed the trial.
GV: What was observed in the HD patients in this trial?
AS: We’re still in the process of getting these next waves of data in. That
will come out over months. It’s important to recognize that the trial just
ended in November. But at this stage we did see a promising safety profile,
meaning that we didn’t have any clinical concerns with the drug.
We saw clear, compelling changes in mutant huntingtin levels in the CSF.
It was sort of gravy in this study. It’s designed as a safety study. We didn’t
know when we entered the study whether we’d be able to even measure
mutant huntingtin in CSF. But it is the best evidence of target engagement
that we have – meaning that it is evidence that the drug is doing what it
ought to do.
We were pleased that the assay [lab test] was developed to the point that
we could use it to measure mutant huntingtin. The test is relatively new
and fortunately came online at about the right time that we needed it.
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The label from the first vial of the Phase 1/2a clinical trial, administered
in London, September 2015 (photo by Gene Veritas)
GV: The reductions of mutant huntingtin “substantially exceeded” your
expectations. To what extent?
FB: When we began the program with Roche, we picked a target level of
reduction of mutant huntingtin in CSF, and, based upon that, we would
decide to go forward with the program [into the next phase].
We put the mutant huntingtin data at the top of the list, because it was the
data that was going to drive a business decision from Roche, but also,
importantly, it was the data that would help them design the next study. So
we prioritized that as being the first thing we would look at. It’s the basis
for telling us what are the doses that we should be using for the next study.
GV: So can you specify the amount of mutant huntingtin reduction?
FB: We’re going to save that for a medical meeting.
Phase 1/2a too early for improving symptoms
GV: You project from your pre-clinical animal studies that the level of
reduction in the brain itself should be greater than what is seen in the
CSF, correct?
FB: Yes. An important nuance for the community is that the level of
reduction that we’re seeing in CSF is not a one-to-one correlation with the
level in [brain] tissue, which is where you want the drug to be working. We
haven’t proven it in patients, but we’re very confident that it will translate
[into higher levels of reduction in the brain].
AS: We’ve tested this drug in several species and are able to understand
that relationship between what you see in CSF versus what you see in
[brain] tissue, which is why it was really important this assay [CSF
measurement] was online. It really is a window into the brain.
To understand that relationship in animals, the animals have to be
sacrificed, to measure the level in the [brain] tissue. So we won’t ever
‘prove’ it in humans, so to speak, but we have a good understanding of it
through the animals. And that it’s consistent from species to species is
comforting. We can draw a conclusion about what’s likely happening in the
human.
GV: Many in the HD community want to know: in this trial, did you see
any signs of disease modification? Were there any hints at all from the
doctors or from the data?
AS: We get anecdotal reports from physicians, but this is a population with
a high placebo effect. These are motivated and excited physicians and
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patients as well. So I wouldn’t read anything into that. It’ll be several
months before we have an understanding, though I would really caution
any expectations along those fronts, because this is a short-term study.
We’re not expecting to see any sort of disease modification, just because of
the way the study was designed. We dosed for three months, but it wasn’t
even full drug effect for three months, because you build up the effect. This
is the precursor to what would be long-term dosing.
GV: Have you observed whether there was also a reduction in the wild
type (normal) huntingtin protein that all HD patients also have?
FB: There isn’t a good assay [lab test] for measuring wild type at this point.
We have the samples, and once the assay is robust enough, we’ll look at it.
The team is working on it, as well as others.
GV: Were there any surprises in the data that you’ve seen so far?
FB: It’s only surprising that it’s worked as we predicted it would [laughter].
Oftentimes when you go from pre-clinical to clinical, things don’t quite
work out as well. But the drug is doing what it should be doing, which is
lowering mutant huntingtin in cerebrospinal fluid. I think it’s all very
positive from that perspective.
Phase 2 versus Phase 3
GV: What have you learned that will be helpful in planning phase 2?
FB: We asked a lot of the sites and the patients – because we collected a
tremendous amount of data from them – for data that will be useful in
designing a Phase 3 trial. We wanted to figure out which of the clinical
outcome measures, which of the imaging measures, is actually
reproducible, robust, and sensitive, to make sure it’s not “noisy” data.
AS: Another important learning will be whether there are differences from
site to site. In a multi-site, multi-country trial, if a particular test just
doesn’t translate well to German, for example, then we’ll have learned that.
We can spare Roche from collecting data that are difficult to interpret,
because they’re difficult to operationalize across sites and countries.
GV: You said “Phase 3” and not Phase 2. Why?
FB: Yes. At this point, Roche has not made a final decision on the next
step. One of the options being considered is going right to a Phase 3 study.
There’s a trade-off. You can do a smaller Phase 2 study – get more data
that make it more probable that you’ll be successful for the Phase 3 – or
you can go directly to a Phase 3 study. Those are the decisions that Roche
is looking at right now very carefully.
The plus side is: if they go right to Phase 3, it would accelerate getting the
drug to market. When we’ve reviewed with them the size of the study and
the time of the study, there’s not a big difference between doing a Phase 3
and doing a more traditional Phase 2 first. It’s more expensive to go right
to Phase 3, but it would save a lot of time.
GV: For an entity such as the FDA, is it okay to go from a Phase 1/2a to a
Phase 3?
FB: The FDA will pay a lot of attention to the safety of the drug which – so
far, knock on wood – looks very good. And then they leave it to the sponsor
whether they want to risk the program. They may advise – because they
ultimately want the drug to be successful, too – that this isn’t the best
thing to do, but ultimately that’s the drug company’s decision. Roche will
engage with the FDA.
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GV: What is leading Roche to think it could maybe go directly to a Phase
3?
FB: It’s safety and tolerability [shown in Phase 1/2a], and the fact that we
now know what dose of the drug produces this level of huntingtin
lowering. Without that, they wouldn’t be able to go to Phase 3, but with
that data, you could say that “this dose” should then produce “this level” of
huntingtin lowering.
GV: Going straight to Phase 3, how much shorter would the whole
program be?
AS: It’s definitely in the years.
FB: Yes, because if they were to do a Phase 2 study first, it would probably
take three years to enroll and run. Roche wants to get this drug to patients
as quickly as possible, assuming it works. They understand the disease.
They understand the need for the patients.
GV: Whether Phase 2 or 3, when would the next study begin?
FB: I would anticipate towards the end of next year.
An important milestone
GV: What is the historical significance of the Ionis breakthrough?
FB: It’s an important milestone for the Huntington’s community. The
mutation in the huntingtin gene was described in 1993. This is the first
drug to go into clinical trials that is directly on target. It addresses the
cause of the disease. We’re extremely excited that we’re actually seeing this
basic science and all the work that NIH and other agencies have funded
over the last 25 years now being translated into something that could
actually have an impact for Huntington’s patients.
This bodes well for other neurological diseases. It has potential to
markedly change how we treat those diseases. Perhaps this technology
platform [the Ionis gene-silencing approach] would be beneficial for them
as well. For patients out there overall, this is extremely important.
(For additional information about next steps in the IONIS-HTTRx
program, click here for a Q & A with Dr. Ed Wild, an advisor and
investigator of the program. You can also read a FAQS from the
Huntington's Disease Society of America by clicking here.)
(Disclosure: I hold a symbolic amount of Ionis shares.)
(In the video below, watch my report on the December 11 Ionis
announcement.)
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News from Ionis: drug reduces toxic Huntington's protein, trial may jump straight to
Phase 3!
from Gene Veritas

05:28

News from Ionis: drug reduces toxic Huntington's protein, trial may jump
straight to Phase 3! from Gene Veritas on Vimeo.
Posted by Gene Veritas at 6:56 AM
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1 comment:
Bev said...
Thanks so much for your excellent questions. I am tempering
my excitement with a dose of realism, but it is wonderful to
have something like HTTRx to look forward to.
5:53 PM, December 18, 2017
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